# To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

> **NCT05491694** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Epirubicin
- **PROCEDURE:** High Intensity Focused Ultrasoun
- **DRUG:** Cyclophosphamide
- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05491694
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491694, "To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05491694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*